TMO:NYE-Thermo Fisher Scientific Inc (USD)

EQUITY | Diagnostics & Research | New York Stock Exchange

Last Closing

USD 555.42

Change

+10.74 (+1.97)%

Market Cap

USD 56.05B

Volume

1.12M

Analyst Target

USD 451.22
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Thermo Fisher Scientific Inc offers analytical instruments, laboratory equipment, software, services, consumables, reagents, chemicals, and supplies to pharmaceutical and biotech companies, hospitals and clinical diagnostic labs.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-07-16 )

Largest Industry Peers for Diagnostics & Research

Symbol Name Price(Change) Market Cap
DHR Danaher Corporation

N/A

USD 143.61B
A Agilent Technologies Inc

N/A

USD 32.44B
IQV IQVIA Holdings Inc

N/A

USD 24.71B
LH Laboratory Corporation of Amer..

N/A

USD 21.86B
DGX Quest Diagnostics Incorporated

N/A

USD 19.12B
QGEN Qiagen NV

N/A

USD 9.85B
CRL Charles River Laboratories

N/A

USD 7.34B
ENZ Enzo Biochem Inc

N/A

USD 0.02B
MTD Mettler-Toledo International I..

N/A

N/A
WAT Waters Corporation

N/A

N/A

ETFs Containing TMO

XDNA 9.55 % 0.00 %

N/A

N/A
SYNB Putnam Biorevolution ETF 8.39 % 0.00 %

N/A

USD 4.89M
LIFE-U:CA Evolve Global Healthcare .. 5.51 % 0.00 %

N/A

N/A
XDG3:XETRA Xtrackers MSCI Global SDG.. 4.53 % 0.00 %

N/A

N/A
AILG 4.51 % 0.00 %

N/A

N/A
XGEN:XETRA Xtrackers MSCI Genomic He.. 4.34 % 0.00 %

N/A

N/A
XGES:LSE Xtrackers MSCI Genomic He.. 4.10 % 0.00 %

N/A

N/A
MHCD:CA Middlefield Healthcare Di.. 4.06 % 0.00 %

N/A

CAD 0.16B
XUHC:SW 4.03 % 0.00 %

N/A

N/A
IUHC:SW iShares S&P 500 Health Ca.. 3.92 % 0.00 %

N/A

N/A
GXLV:LSE SPDR® S&P® U.S. Health .. 3.92 % 0.00 %

N/A

N/A
WH2E:XETRA Invesco S&P World Health .. 3.83 % 0.00 %

N/A

N/A
SXLV:SW SPDR S&P U.S. Health Care.. 3.20 % 0.00 %

N/A

N/A
XSHC:LSE Xtrackers MSCI USA Health.. 3.09 % 0.00 %

N/A

USD 0.65B
XUHC:LSE Xtrackers MSCI USA Health.. 3.09 % 0.00 %

N/A

USD 0.65B
HEAW:LSE SPDR® MSCI World Health .. 2.71 % 0.00 %

N/A

N/A
ABIE:XETRA AXA IM ACT Biodiversity E.. 2.62 % 0.00 %

N/A

N/A
CDNA:CA 2.59 % 0.00 %

N/A

N/A
FOHW:XETRA Franklin Future of Health.. 2.52 % 0.00 %

N/A

N/A
ABIT:XETRA AXA IM ACT Biodiversity E.. 2.44 % 0.00 %

N/A

N/A
CURE Direxion Daily Healthcare.. 2.32 % 1.06 %

N/A

USD 0.14B
ABIE:F AXA IM ACT Biodiversity E.. 2.23 % 0.00 %

N/A

N/A
ABIT:F AXA IM ACT Biodiversity E.. 1.95 % 0.00 %

N/A

N/A
XMLH:F Legal & General Ucits Etf.. 1.91 % 0.00 %

N/A

N/A
HYLG 1.84 % 0.00 %

N/A

N/A
JPST JPMorgan Ultra-Short Inco.. 0.74 % 0.00 %

N/A

USD 31.53B
FHLC Fidelity® MSCI Health Ca.. 0.00 % 0.08 %

N/A

USD 2.37B
IBLN 0.00 % 0.64 %

N/A

N/A
IXJ iShares Global Healthcare.. 0.00 % 0.46 %

N/A

N/A
IYH iShares U.S. Healthcare E.. 0.00 % 0.43 %

N/A

N/A
JHMH 0.00 % 0.46 %

N/A

N/A
LDUR PIMCO Enhanced Low Durati.. 0.00 % 1.02 %

N/A

USD 0.91B
JMIN 0.00 % 0.12 %

N/A

N/A
ACT Enact Holdings Inc 0.00 % 0.75 %

N/A

USD 5.50B
KORP American Century Diversif.. 0.00 % 0.45 %

N/A

USD 0.49B
LS:CA 0.00 % 2.21 %

N/A

N/A
HWF:CA 0.00 % 0.00 %

N/A

N/A
CGAA:CA CI Global Asset Allocatio.. 0.00 % 0.00 %

N/A

CAD 0.02B
RXD ProShares UltraShort Heal.. 0.00 % 0.77 %

N/A

N/A
RXD ProShares UltraShort Heal.. 0.00 % 0.95 %

N/A

N/A
RXL ProShares Ultra Health Ca.. 0.00 % 0.95 %

N/A

N/A
VHT Vanguard Health Care Inde.. 0.00 % 0.10 %

N/A

N/A
XHC:CA iShares Global Healthcare.. 0.00 % 0.65 %

N/A

CAD 0.56B
XLV Health Care Select Sector.. 0.00 % 0.13 %

N/A

USD 33.98B
IHCU:LSE iShares S&P 500 Health Ca.. 0.00 % 0.00 %

N/A

N/A
IUHC:LSE iShares S&P 500 USD Healt.. 0.00 % 0.00 %

N/A

USD 2.40B
SXLV:LSE SPDR S&P U.S. Health Care.. 0.00 % 0.00 %

N/A

N/A
WHEA:LSE SPDR® MSCI World Health .. 0.00 % 0.00 %

N/A

N/A
XDWH:LSE Xtrackers MSCI World Heal.. 0.00 % 0.00 %

N/A

N/A
XFVT:LSE Xtrackers FTSE Vietnam Sw.. 0.00 % 0.00 %

N/A

N/A
QDVG:F iShares S&P 500 Health Ca.. 0.00 % 0.00 %

N/A

N/A
XUHC:F Xtrackers (IE) Public Lim.. 0.00 % 0.00 %

N/A

USD 0.85B
ZPDH:F SPDR S&P U.S. Health Care.. 0.00 % 0.00 %

N/A

USD 0.40B
DXSI:XETRA Xtrackers - Stoxx Europe .. 0.00 % 0.00 %

N/A

USD 0.02B
QDVG:XETRA iShares S&P 500 Health Ca.. 0.00 % 0.00 %

N/A

N/A
XDWH:XETRA Xtrackers MSCI World Heal.. 0.00 % 0.00 %

N/A

N/A
XUHC:XETRA Xtrackers MSCI USA Health.. 0.00 % 0.00 %

N/A

N/A
ZPDH:XETRA SPDR S&P U.S. Health Care.. 0.00 % 0.00 %

N/A

N/A
HIG-U:CA 0.00 % 0.00 %

N/A

N/A
ZGEN:CA 0.00 % 0.00 %

N/A

N/A
LONG:CA CI Global Longevity Econo.. 0.00 % 0.00 %

N/A

CAD 3.64M
XMLH:XETRA L&G Healthcare Breakthrou.. 0.00 % 0.00 %

N/A

N/A
OUFH:XETRA 0.00 % 0.00 %

N/A

N/A
IXJ:AU Ishares Global Healthcare.. 0.00 % 0.00 %

N/A

USD 1.47B
DWEQ 0.00 % 0.00 %

N/A

N/A
DOCT:SW L&G Healthcare Breakthrou.. 0.00 % 0.00 %

N/A

USD 0.06B
SROI Calamos Antetokounmpo Glo.. 0.00 % 0.00 %

N/A

N/A
CFCV 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Diagnostics & Research) Market Performance vs. Exchange (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 4.64% 77% C+ 47% F
Dividend Return 0.15% 29% F 3% F
Total Return 4.79% 77% C+ 40% F
Trailing 12 Months  
Capital Gain 6.06% 77% C+ 50% F
Dividend Return 0.15% 17% F 2% F
Total Return 6.21% 69% C- 39% F
Trailing 5 Years  
Capital Gain 89.09% 92% A 84% B
Dividend Return 1.70% 20% F 5% F
Total Return 90.79% 92% A 82% B
Average Annual (5 Year Horizon)  
Capital Gain 16.88% 85% B 81% B-
Dividend Return 17.10% 77% C+ 79% B-
Total Return 0.22% 17% F 6% D-
Risk Return Profile  
Volatility (Standard Deviation) 23.28% 69% C- 45% F
Risk Adjusted Return 73.45% 100% F 89% A-
Market Capitalization 56.05B 100% F 99% N/A

Key Financial Ratios

  Ratio vs. Industry/Classification (Diagnostics & Research) Ratio vs. Market (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 35.20 50% 19%
Price/Book Ratio 4.62 46% 19%
Price / Cash Flow Ratio 24.89 31% 12%
Price/Free Cash Flow Ratio 21.90 31% 12%
Management Effectiveness  
Return on Equity 13.62% 62% 69%
Return on Invested Capital 8.92% 54% 62%
Return on Assets 4.82% 54% 71%
Debt to Equity Ratio 67.01% 38% 50%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

High dividend returns

The stock has outperformed its sector peers on average annual dividend returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile. This can be a good buy, especially if it is outperforming on total return basis , for investors seeking high income yields.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Dividend Growth

This stock has shown below median dividend growth in the previous 5 years compared to its sector.